J B Chemicals & Pharmaceuticals Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/1ok644vt954ohzrkweeflxo2.pdf

Key Takeaways


Domestic Business Performance

Chopra: "we want to grow the profits better than the topline and basically create value for all our stakeholders and build our organization which is more progressive and future ready."

Margin & Cost Structure

Chopra: "what we want to also comment that our overall EBITDA margins would be on the higher side of the guidance that we are giving to the market."

International Business & CDMO


Ophthalmology & Strategic Bets


Guidance & Commitments

CommitmentSpecificsTimeline
Operating EBITDA marginOn the higher side of the 26% to 28% guidance bandFY25
Domestic business growthMid-teens (12-14%), outperforming the IPM (8-10%)FY25
CDMO growthDouble-digit growth, with realization momentum from H2FY25
South Africa businessMid-teen growthFrom Q2 onwards
International business overallDouble-digit growthFrom Q3 onwards
Ophthalmology portfolio run rateRs. 180 crore+ annualizedFY25
Debt repaymentRepay all remaining debt (~Rs. 108 crore) in equal quarterly installmentsBy March FY25
Gross marginMaintain 65%-66% rangeGoing ahead

Key Metrics

MetricQ1 FY25
Revenue₹1,004 cr, +12% YoY
Domestic revenue₹595 cr, +22% YoY
International revenue₹409 cr, flat YoY
CDMO revenue₹106 cr, muted due to weak cough and cold season
Gross margin66.2%, +80 bps YoY
Operating EBITDA (excl. ESOP)₹292 cr, +20% YoY
Operating EBITDA margin (excl. ESOP)29%, +190 bps YoY
Profit after tax₹177 cr, +25% YoY
Employee cost (incl. ESOP)₹167 cr, +12% YoY
ESOP cost4% of reported EBITDA vs 5% YoY
Other expense as % of salesimproved by 130 bps YoY
Gross debt₹108 cr, reduced from ₹357 cr as of 31 Mar 2024
Net cash position₹313 cr
Domestic volume growth (IQVIA)+4%, 300 bps above IPM volume growth
Domestic growth breakdown+4% volume, ~6% price, ~2% new introductions
Domestic organic growth (excl. Ophthalmology)+13% YoY
Ophthalmology portfolio annualized run rate₹180 cr+ expected in FY25, up from ~₹160 cr last year
Sporlac brand revenue₹100 cr, 20% CAGR over 3 years
Razel franchise revenue₹89 cr, +29% as per IQVIA MAT Jun 2024
Azmarda monthly demand120,000–125,000 units steady state
CDMO growth outlookdouble-digit growth expected for FY25, pickup from Sep onwards
Operating EBITDA margin guidance26% to 28%, expected on higher side
Domestic growth guidance12% to 14% (mid-teens)
Interest cost expected for Q2 FY25~₹3 cr, down from ₹6 cr in Q1
ESOP charge guidance for FY25₹42–45 cr